Overview - The company is pleased with its performance in fiscal Q3, highlighting successful product launches and overall execution by the team [1] Group 1: Product Performance - Key product launches, including the Pro iQ single-quad and the 8850, have resonated well in the market [1] - The Infinity III replacement cycle has also contributed positively to the company's performance [1] Group 2: Services Business - The services business is critical for the company, enhancing customer satisfaction and underpinning overall performance [2]

Group 1 - The company reported strong top-line growth of 6% in the third quarter, particularly driven by the pharma and CAM sectors [1][2] - The revenue guidance for 2025 has been increased, indicating broad-based growth with significant contributions from pharma, CAM, and CDMO [2] - Key innovations such as Infinity III, Pro iQ Plus on the LC/MS side, and 8850 innovations have resonated well in the market, contributing to the growth [2] Group 2 - The service business achieved customer satisfaction scores greater than 90%, highlighting the importance of customer intimacy in the current environment [2] - The pharma sector showed strong performance, with small molecule QA/QC leading the growth [2]